Drug Trial Radar · NCT07240376
Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome
Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Nov 25, 2025
Primary completion
Dec 31, 2026
Study completion Feb 28, 2027
Sponsor
- Lead sponsor
- Huazhong University of Science and TechnologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Renmin Hospital of Wuhan University; Wuhan TongJi Hospital
- First posted
- Nov 20, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if Stapokibart (CM310) works to treat Non-Allergic Rhinitis with Eosinophilia Syndrome (NARES) in adults. It will also learn about the safety of CM310. The main questions it aims to answer are: Does drug CM310 relieve the symptoms of participants? What medical problems do participants have when injecting CM310? Researchers will compare CM310 to a placebo (a look-alike substance that contains no drug) to see if CM310 works to treat NARES. Participants will: Inject CM310 or a placebo every 2 weeks for 12 weeks, and follow up for another 8 weeks. Visit the clinic once every 2 weeks for checkups and tests. Keep a diary of their symptoms every day.
Conditions
- Non-Allergic Rhinitis With Eosinophilia Syndrome
Interventions
Stapokibart (CM310)Biological
Paticipants were given CM310 (with an initial dose of 600 mg followed by 300mg subcutaneous injection, once every two weeks) for 12 weeks. Follow up for another 8 weeks.During the treatment period, mometasone furoate was sprayed nasal every day
PlaceboOther
After enrollment, paticipants were given a placebo (subcutaneous injection, with the same dose as the experimental group, once every two weeks) for 12 weeks. Follow up for another 8 weeks. During the treatment period, mometasone furoate was sprayed nasal every day
Primary outcomes
What the sponsor says the trial is designed to measure.
- The mean change from baseline in the Reflective Total Nasal Symptom Score (rTNSS) at Week 12.Time frame: From enrollment to the end of treatment at 12 weeks
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Beijing Tsinghua Changgung Hospital
Beijing, China
Eye & Ent Hospital of Fudan University
Shanghai, China
Clifford Hospital
Guangzhou, Guangdong, China
Renmin Hospital of Wuhan University
Wuhan, Hubei, China
Tongji hospital, Tongji medical college, Huazhong University of Science and Technology
Wuhan, Hubei, China
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
Hubei Provincial Hospital of Integrated Chinese and Western Medicine
Wuhan, Hubei, China
The Central Hospital of Wuhan
Wuhan, Hubei, China
Xiangyang Central Hospital
Xiangyang, Hubei, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.